EX-23.2 8 apls-ex232_12.htm EX-23.2 CONSENT OF EY apls-ex232_12.htm

Exhibit 23.2

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the following Registration Statements:

 

 

(1)

Registration Statements (Form S-3 Nos. 333-235830 and 333-229091) of Apellis Pharmaceuticals, Inc., and

 

(2)

Registration Statement (Form S-8 No. 333-236710) pertaining to the 2020 Inducement Stock Incentive Plan of Apellis Pharmaceuticals, Inc., and

 

(3)

Registration Statement (Form S-8 No. 333-236708) pertaining to the 2017 Stock Incentive Plan and Stock Option Inducement Awards (March 2019-February 2020) of Apellis Pharmaceuticals, Inc., and

 

(4)

Registration Statement (Form S-8 No. 333-229876) pertaining to the 2017 Stock Incentive Plan, Inducement Stock Option Award, and 2017 Employee Stock Purchase Plan of Apellis Pharmaceuticals, Inc., and

 

(5)

Registration Statement (Form S-8 No. 333-221528) pertaining to the 2010 Equity Incentive Plan, 2017 Stock Incentive Plan, and 2017 Employee Stock Purchase Plan of Apellis Pharmaceuticals, Inc.;

 

of our report dated February 26, 2019, with respect to the consolidated financial statements of Apellis Pharmaceuticals, Inc. included in this Annual Report (Form 10-K) of Apellis Pharmaceuticals, Inc. for the year ended December 31, 2020.

/s/ Ernst & Young LLP

Boston, Massachusetts

February 25, 2021